Sarcopenia is one of the quiet epidemics of an aging world. It is diagnosed when both muscle strength and muscle quantity fall below defined thresholds, and it predicts falls, fractures, hospitalization, and death. Yet the biology behind it remains only partly understood. Most research has focused on neuromuscular decline, protein metabolism, chronic inflammation, and inactivity. The new study turns attention to a less obvious suspect: the network of tiny blood vessels that feeds muscle tissue, and the molecular signals that build and maintain that network.

Angiogenesis — the sprouting of new capillaries from existing vessels — is essential to muscle health. Every muscle fiber depends on a dense microcirculation to deliver oxygen, glucose, amino acids, and hormones, and to clear metabolic waste. When a muscle is injured, new vessel formation is one of the earliest events in repair, preceding the regeneration of the muscle fibers themselves. As people age, capillary density in skeletal muscle falls, a process called capillary rarefaction, and the decline is most pronounced around the fast-twitch type II fibers that sarcopenia strips away first. Human biopsy studies have linked this vascular thinning directly to weaker grip, smaller appendicular muscle mass, and poorer physical performance.

The research team, led by Hui Li and Feng Jia of Nanyang Central Hospital together with colleagues at the Seventh People’s Hospital of Zhengzhou, measured three serum angiogenesis markers using enzyme-linked immunosorbent assays: VEGF, the master driver of new vessel growth; ANGPT1, which stabilizes and matures vessels; and ANGPT2, which antagonizes ANGPT1 and promotes vessel remodeling. Fasting blood samples were drawn the morning after admission, processed under standardized conditions, stored at minus 80 degrees Celsius, and assayed in duplicate by laboratory staff blinded to each patient’s clinical status. Quality controls kept measurement variability below 10 percent within assays and below 15 percent between batches spread across five years.

Sarcopenia was defined according to the Asian Working Group for Sarcopenia criteria, requiring both reduced hand grip strength and reduced appendicular skeletal muscle mass. Grip was tested with a calibrated dynamometer in a standardized seated posture, three trials per hand, with the best value recorded. Muscle mass was estimated by multi-frequency bioimpedance analysis using an eight-frequency device that measured each limb separately, performed after an overnight fast with strict controls for hydration status. Of the 471 participants, 68 — or 14.44 percent — met the criteria for sarcopenia.

The results were striking in their consistency. Patients with sarcopenia had significantly lower VEGF — an average of 116.95 picograms per milliliter versus 138.60 in those without the condition — and dramatically lower ANGPT1, at 23.68 nanograms per milliliter versus 34.15. ANGPT2, by contrast, showed no meaningful difference. In regression models adjusted first for age, sex, and body mass index, and then further for comorbidity burden, hemoglobin, albumin, smoking, alcohol use, and hypertension, VEGF remained positively correlated with both grip strength and muscle mass, while ANGPT1 held its association with muscle mass and, in the fully adjusted model, with grip strength as well.

The risk statistics are the headline numbers. Using receiver operating characteristic analysis, the team derived cutoff values — VEGF at or below 102.55 picograms per milliliter and ANGPT1 at or below 19.47 nanograms per milliliter — and validated them with ten-fold cross-validation to guard against overestimation. In fully adjusted logistic models, low VEGF was associated with roughly a threefold higher odds of sarcopenia (odds ratio 3.360), and low ANGPT1 with even greater odds (3.709, p < 0.001). Among patients with low ANGPT1, more than a quarter — 25.55 percent — had sarcopenia, compared with fewer than 10 percent of those with normal levels. Adding either marker to a base clinical model built from age, sex, BMI, comorbidities, and routine labs significantly improved the model’s statistical fit, with ANGPT1 delivering the largest gain.

Why would vessel-building signals track so closely with failing muscle? The authors propose a dual-hit mechanism rooted in the aging muscle’s microenvironment. Endothelial cells and satellite cells — the stem cells that rebuild muscle — sit side by side and exchange chemical messages. VEGF acts directly on satellite cell receptors to trigger their activation, proliferation, and migration after injury; ANGPT1 then supports their survival and coordinates their differentiation and fusion into mature, multinucleated muscle fibers. When circulating VEGF and ANGPT1 both fall, the regenerative sequence is disrupted at both ends: the vascular supply shrinks and the stem cell pipeline stalls, leaving chronic micro-injuries to heal poorly — the hallmark of sarcopenic muscle. Animal work supports the plausibility: VEGF gene delivery improves muscle ischemia and repair in rodents, and ANGPT1 enhances regeneration in mice, while exercise and even massage raise VEGF expression in skeletal muscle.

The study’s limitations deserve equal billing. It is cross-sectional, so it cannot say whether low angiogenic markers cause muscle loss or simply reflect it — reverse causation remains a real possibility. Serum VEGF and ANGPT1 are systemic signals, not direct measurements of the muscle microenvironment, and their blood levels can be swayed by subclinical disease, inflammation, nutrition, and activity. The cohort was drawn from a single hospital’s gastroenterology and general surgery service rather than the community, and physical performance testing was unavailable, preventing severity grading. The diagnostic discrimination of the markers alone was modest — area under the curve of 0.641 for VEGF and 0.668 for ANGPT1 — meaning they add incremental value to clinical assessment rather than replacing it. ANGPT2, notably, contributed nothing once confounders were accounted for.

Even with those caveats, the findings open an intriguing therapeutic window. If the vascular niche truly governs the regenerative failure of aging muscle, then interventions that boost angiogenesis — exercise training being the most proven, with hypoxic training, pneumatic compression, and gene therapy as research frontiers — might slow or partially reverse sarcopenia. And if larger, longitudinal, community-based studies confirm that a routine blood draw can flag failing muscle years before a fall, sarcopenia screening could shift from the grip dynamometer to the phlebotomy tray. For now, the message is measured but provocative: the health of aging muscles may be written, in part, in the chemistry of their blood supply.

Subject of Research: Associations between serum angiogenesis markers VEGF and ANGPT1 and sarcopenia in older adults

Article Title: Relationships between serum angiogenesis markers and sarcopenia: a cross-sectional study

Article References: Li, H., Liu, H., Liu, Y., Shi, W., Shi, L., & Jia, F. (2026). Relationships between serum angiogenesis markers and sarcopenia: a cross-sectional study. Frontiers in Medicine, 13, Article 1922045. https://doi.org/10.3389/fmed.2026.1922045

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.1922045

Keywords: sarcopenia, angiogenesis, VEGF, ANGPT1, aging, muscle loss, blood vessels, biomarkers, geriatric medicine, cross-sectional study, hand grip strength, muscle regeneration

Sarcopenic obesity is a condition in which excess adiposity coexists with reduced muscle mass and reduced muscle function. It matters because the two components feed each other in a vicious loop. Obesity accelerates muscle loss through chronic low-grade inflammation, insulin resistance and oxidative stress, while declining muscle mass lowers resting energy expenditure and encourages further fat accumulation. Shared drivers—aging itself, physical inactivity and chronic disease—perpetuate the cycle. Estimates of how common the condition is have varied wildly across studies precisely because researchers kept defining it differently: some used low strength plus a high body mass index, others low muscle mass plus high waist circumference, and still others required both muscle deficits alongside excess fat. A recent meta-analysis put the global prevalence at roughly 11 percent among adults aged 60 and older, rising to about 23 percent past age 75, but those numbers are hard to compare when the yardsticks differ.

The Taiwan study drew on the Taiwan Initiatives for Geriatric Epidemiological Research, recruiting 446 eligible participants from a senior health check-up programme at National Taiwan University Hospital between 2015 and 2017. After excluding people with prevalent dementia, neurological conditions, missing data or a body mass index below 18.5 kilograms per square metre, the final analytic sample comprised 366 older adults with a median age of 75, about 55 percent of them women. Each participant underwent a baseline assessment and a repeat evaluation two years later. Muscle mass was estimated with bioelectrical impedance analysis and normalized by body weight, with the lowest sex-specific quartile classified as low. Handgrip strength was measured with a dynamometer using Asian Working Group for Sarcopenia cutoffs of less than 28 kilograms for men and less than 18 kilograms for women. Obesity was defined as a body mass index of at least 27, a threshold specific to Taiwanese adults rather than the conventional cutoff of 30.

Cognition was assessed with a battery of neuropsychological tests at both visits. Global cognition was measured with the Taiwanese version of the Montreal Cognitive Assessment, while domain-specific measures included immediate and delayed logical memory recall, attention via the Trail Making Test A and digit span tasks, executive function via the Trail Making Test B, and semantic verbal fluency. The researchers then used generalized linear mixed models—statistical frameworks that handle repeated measurements within the same person—to estimate how phenotype status related to cognitive performance, adjusting for age, sex, education, the APOE ε4 allele, depressive symptoms, smoking, alcohol use, hypertension, diabetes, dyslipidemia, heart disease, physical activity, and blood levels of the inflammatory markers C-reactive protein and interleukin-6.

The results were striking. Of the 366 participants, 303 had neither sarcopenia nor obesity, 20 had sarcopenia alone, 27 had obesity alone, and 16—about 4 percent—met the full consensus criteria for sarcopenic obesity. That small group stood out. Compared with people who had neither condition, those with sarcopenic obesity scored nearly one point lower on the Montreal Cognitive Assessment (a beta coefficient of −0.96), and showed significantly poorer immediate free recall and attention on the Trail Making Test A. Obesity alone, by contrast, was linked only to poorer executive function on the Trail Making Test B, and sarcopenia alone showed no robust association with global cognition. When the researchers modeled baseline status and its interaction with follow-up time, baseline sarcopenic obesity predicted poorer executive function over time, suggesting the phenotype marks not just a snapshot of lower performance but a trajectory of decline.

The team also examined a related, simpler phenotype called dynapenic obesity—the combination of low muscle strength and obesity without any requirement for measured muscle loss. Because grip strength is far easier to assess than muscle mass in clinics and community settings, dynapenic obesity has long been proposed as a pragmatic screening tool, though it has often been conflated with sarcopenic obesity in the literature. In this cohort, the two phenotypes overlapped completely: all 16 participants with dynapenic obesity also met the criteria for sarcopenic obesity. Dynapenic obesity was associated with even slightly larger deficits—about −1.15 points on the Montreal Cognitive Assessment—along with poorer memory and attention, and a significant interaction with time for executive function. The authors are careful to stress that this overlap means the two phenotypes cannot be treated as independent entities here; the findings speak to a shared, strength-based signal of muscle–adiposity imbalance rather than proof that grip strength outperforms muscle mass measurement.

Robustness was tested aggressively. When obesity was redefined using Asian-specific waist circumference cutoffs (90 centimetres for men, 80 for women), sarcopenic obesity remained associated with poorer global cognition and attention. When obesity was defined by the highest sex-specific quartile of fat mass index, the association with global cognition and memory persisted. Alternative thresholds for low muscle mass—the lowest tertile and quintile—produced the same conclusions, and re-including seven participants excluded solely for being underweight left the results essentially unchanged. Exploratory stratified analyses hinted at who may be most vulnerable: associations with poorer global cognition appeared among women, among people without the APOE ε4 allele, and among those in the highest tertile of interleukin-6 or C-reactive protein, even though the participants’ inflammatory marker levels generally fell below clinical thresholds for overt inflammation. These subgroup findings, the authors caution, were not adjusted for multiple comparisons and must be treated as hypothesis-generating.

Why might a muscle–fat imbalance reach the brain? The mechanisms are likely multifactorial. Age-related muscle decline and physical inactivity promote adiposity, insulin resistance and systemic low-grade inflammation, which in turn can impair muscle metabolism, damage the vasculature and drive neuroinflammation. The observation that cognitive deficits clustered in participants with relatively higher interleukin-6 or C-reactive protein is compatible with such inflammatory pathways, and the pattern of stronger associations among people without diabetes suggests metabolic context matters. There may also be sex-specific biology at work, including differences in inflammatory profiles and sex hormones that influence skeletal muscle aging. But the study is observational, and reverse causality cannot be excluded: early cognitive impairment may itself reduce physical activity and alter body composition long before dementia is diagnosable.

The practical takeaway may prove to be the study’s most consequential contribution. A grip dynamometer and a bathroom scale are cheap, fast and universally available. If the combination of weak grip and elevated body mass index flags older adults at risk of early cognitive impairment, it offers a first-step, community-based screening strategy that could direct people toward fuller evaluations of body composition and cognition before irreversible decline sets in. The authors emphasize that the clinical utility of this approach requires validation in larger cohorts with more balanced distributions of muscle mass and strength, longer follow-up, and objective measures of physical activity. Still, in a world where both obesity and population aging are accelerating simultaneously, the message is hard to ignore: what matters for the aging brain may not be fat or muscle alone, but the dangerous arithmetic of losing one while gaining the other.

Subject of Research: Associations of consensus-defined sarcopenic obesity and dynapenic obesity with early cognitive impairment in older adults

Article Title: Consensus‐Defined Sarcopenic Obesity and a Related Dynapenic Obesity Phenotype in Relation to Early Cognitive Impairment

Article References: Wang, M.-C., Peng, T.-C., Chiou, J.-M., Chen, Y.-C., & Chen, J.-H. (2026). Consensus‐Defined Sarcopenic Obesity and a Related Dynapenic Obesity Phenotype in Relation to Early Cognitive Impairment. Journal of Cachexia, Sarcopenia and Muscle, 17(5), Article e70395. https://doi.org/10.1002/jcsm.70395

Image Credits: AI Generated

DOI: 10.1002/jcsm.70395

Keywords: sarcopenic obesity, dynapenic obesity, cognitive impairment, aging, muscle mass, handgrip strength, obesity, ESPEN-EASO consensus, inflammation, APOE ε4, cohort study, geriatric health

The clearest longitudinal signal ran from muscle traits to later osteoporosis. Participants with higher appendicular lean mass, stronger hand grips or faster usual walking speeds had lower observed risks of developing osteoporosis. For each standardised increase in the three measures, the reported hazard ratios were 0.830 for adjusted lean mass, 0.544 for grip strength and 0.735 for walking pace. A hazard ratio below one indicates a lower event rate in the model, although it does not by itself prove that improving the trait would prevent disease. When the three muscle measures were adjusted for one another, grip strength and walking pace remained independently associated with lower osteoporosis risk, with hazard ratios of 0.593 and 0.788. The exposure–response patterns were broadly monotonic for these functional measures: risk fell as strength and walking speed increased. Analyses also detected interactions with age, sex and body-mass index. The associations were generally stronger in younger adults; lean mass and walking pace had larger effects in men, while lean mass showed a stronger relationship among people with lower BMI. Even within these subgroups, however, favourable muscle traits were consistently associated with lower risk.

Muscle mass itself produced a less straightforward result. Adjusted appendicular lean mass showed a U-shaped association with osteoporosis, meaning that neither the lowest nor the highest levels appeared optimal in the statistical model. This finding is exploratory and does not demonstrate that unusually high muscle mass causes bone loss. The authors propose several possible explanations that require testing, including overtraining, inadequate energy availability and exercise-related hormonal disruption. Muscles normally load the skeleton through contraction, encouraging bone adaptation, but that response may reach a ceiling. Prolonged fatigue, irregular forces or abnormal stress distribution could alter the benefit of loading and contribute to skeletal microdamage. Intense training combined with low energy availability has also been linked to impaired bone health, while hormonal disruption may add to the risk. These possibilities should not be read as evidence that ordinary physical activity is harmful. Rather, the unusual curve highlights the limitations of interpreting a single measure of lean mass without detailed information about training intensity, nutrition, hormones, body composition and previous injuries. Replication in other populations will be needed before the pattern can influence advice or clinical practice.

The association also ran in the opposite direction. In longitudinal analyses, people with higher left- or right-heel BMD, or higher heel BMD T-scores, were less likely to develop probable sarcopenia. The relationship was broadly monotonic: as heel density rose, sarcopenia risk fell. Complementary analyses using BMD measured at the femoral neck and lumbar spine by dual-energy X-ray absorptiometry supported inverse associations with both probable sarcopenia and confirmed sarcopenia. The primary sarcopenia definition was “probable sarcopenia”, based on low grip strength alone—below 27 kilograms in men or 16 kilograms in women—while confirmed sarcopenia additionally required low adjusted appendicular lean mass. Genetic analyses added evidence of two-way effects. Mendelian randomisation indicated that most sarcopenia-related traits, but not usual walking pace, had effects on lumbar-spine BMD. In the reverse analysis, lumbar-spine BMD showed effects on most sarcopenia traits, again excluding walking pace. Mendelian randomisation uses genetic variants as instruments to reduce some confounding, but its validity depends on assumptions about those variants. It is not a substitute for a randomised intervention trial.

The investigators next searched for circulating molecules that might help explain how muscle status relates to bone. Mediation analysis identified 465 proteins associated with the lean-mass measure, 706 associated with grip strength and 697 associated with walking pace in pathways leading statistically towards osteoporosis risk. Of these, 352 were shared across all three muscle traits. The metabolite analysis identified 21 potential mediators for lean mass, 140 for grip strength and 127 for walking pace, including 17 shared across the three measures. Because exposure, mediator and outcome were not measured repeatedly in a way that established their temporal order, these results indicate statistical mediation consistent with a biological pathway, not proof that a particular protein or metabolite causes muscle loss to produce osteoporosis. To investigate where the proteins might arise, the researchers compared their signals with single-cell RNA-sequencing data from 90,902 cells taken from intercostal muscles of 17 donors in a human skeletal-muscle ageing atlas. Mediator-related expression was especially enriched in myeloid, endothelial and stromal cells. These cell groups participate in immune regulation, blood-vessel biology and connective-tissue maintenance, suggesting that muscle-to-bone communication may involve secreted signals and local cellular networks as well as mechanical loading.

Genetic and biomarker analyses pointed to a common background for the two disorders. Across the genome, the estimated genetic correlation between sarcopenia and osteoporosis risk was 0.25. Local analysis identified 102 genomic regions with significant heritability for both traits; 12 also showed significant local genetic correlation, and 10 of those correlations were positive. Polygenic risk scores provided a similar pattern: a higher genetic risk score for sarcopenia was associated with osteoporosis prevalence and incidence, while an osteoporosis score was associated with both the prevalence and incidence of sarcopenia. Circulating biomarkers overlapped extensively as well. Of 226 metabolites associated with sarcopenia, 164—71 per cent—were also associated with osteoporosis, all in the same direction. Among 1,576 sarcopenia-associated proteins, 502—31.3 per cent—were also linked to osteoporosis; 500 had concordant directions of association. Most of the shared proteins were secreted molecules whose gene activity was enriched in immune and lymphoid tissues. A protein–protein interaction network was far more connected than expected by chance, with immune-regulatory nodes including IL6, CXCL8 and TNF. These are associations, not diagnostic markers or validated treatment targets.

The biological pathways highlighted by the analysis offer a plausible bridge between muscle and bone. Enriched pathways included T-helper-17-cell differentiation, interleukin-17 signalling and NF-κB signalling. Chronic inflammatory activity can promote muscle protein breakdown and atrophy, while inflammatory signalling in bone can stimulate osteoclasts, the cells responsible for bone resorption. Several regulatory factors identified in the analysis have established roles across these processes, including NFKB1, RELA, FOXO1, SIRT1 and the vitamin D receptor. Other candidates included TFAM, which is involved in mitochondrial DNA maintenance; MGP, a vitamin K-dependent protein involved in mineral regulation and also linked to muscle development; and COMMD7, which has been connected with NF-κB activity. However, the gene-expression results demand caution. Transcriptome-wide association and summary-data Mendelian-randomisation analyses found dozens of genes nominally associated with both conditions in several tissues, and about 70 per cent showed consistent effect directions. After correction for multiple testing, no single gene remained significantly associated with both diseases simultaneously. The authors therefore describe these findings as exploratory clues rather than confirmed mechanisms. Similar caution applies to the large lists of proteins and metabolites: shared statistical signals need experimental validation.

The study also found common patterns for several potentially modifiable factors. Greater adult smoking exposure, measured in pack-years, was associated with higher prevalence of both sarcopenia and osteoporosis. Sleep duration showed a U-shaped relationship: sleeping fewer than six hours or more than eight hours was associated with greater risk than sleeping six to eight hours. More physical activity was associated with lower prevalence of both disorders up to a point, after which the association was no longer statistically significant. These observations do not establish that changing sleep duration or activity to a particular level will prevent either condition, and the study cannot distinguish all the reasons why people sleep or exercise more or less. Still, the molecular analyses found substantial overlap in the proteins and metabolites associated with these exposures and both diseases—roughly 30.5 to 73 per cent depending on the factor and analysis. Smoking and short sleep shared mediators linked to inflammation, oxidative stress, lipid metabolism and gastrointestinal function. Physical activity shared metabolic mediators, particularly involving lipid metabolism. The patterns are consistent with a muscle–bone unit influenced by systemic inflammation and metabolic health, while supporting established preventive priorities such as avoiding tobacco and maintaining appropriate physical activity and sleep.

Several limitations define what can be concluded. The primary sarcopenia outcome relied on grip strength alone, which may misclassify people whose muscle mass or mobility differs from their hand strength. The timing of sarcopenia onset was also uncertain; people who developed it between the baseline and imaging visits may have been excluded from some analyses because of progression or death. Heel BMD, the main osteoporosis trait, was estimated with quantitative ultrasound because baseline measurements at other skeletal sites were unavailable. Heel ultrasound is not universally considered the diagnostic gold standard, so findings should be tested using femoral-neck or lumbar-spine DXA measurements. UK Biobank participants may not represent the wider population, and the genetic analyses were based on people of Caucasian ancestry, limiting generalisability. Residual confounding could also have inflated some overlaps among diseases, proteins and metabolites. The research therefore does not show that one condition inevitably causes the other, nor that a specific supplement, exercise programme or drug will treat both. Future work should replicate the associations in diverse cohorts, measure molecular intermediaries repeatedly over time, test candidate pathways in cells and animal models, and evaluate integrated interventions. Clinically, the results argue for viewing muscle strength, mobility and bone health together rather than as isolated features of ageing—and for determining whether that integrated approach can reduce the combined burden of osteosarcopenia.

Subject of Research: The bidirectional relationship and shared biological mechanisms between sarcopenia and osteoporosis.

Article Title: Bidirectional Relationship and Shared Mechanisms Between Sarcopenia and Osteoporosis: An Observational Study Integrating Genomic, Proteomic, and Metabolomic Data.

Article References: Original research article.

DOI: 10.1111/acel.70617.

Keywords: Sarcopenia; osteoporosis; osteosarcopenia; bone mineral density; muscle strength; proteomics; metabolomics; genetics; inflammation; ageing.